TERN-501 is under clinical development by Terns Pharmaceuticals and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase II drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the TERN-501 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TERN-501 overview

TERN-501 is under development for the treatment of nonalcoholic steatohepatitis(NASH) and obesity. It acts by activation of thyroid hormone receptor beta (TR-Beta). Thyroid hormone receptor belongs to the class of nuclear receptors.Thyroid hormone receptor belongs to the class of nuclear receptors.The drug candidate is administered through oral route.

Terns Pharmaceuticals overview

Terns Pharmaceuticals is a biopharmaceutical company that develops single-agent and combination drugs targeting non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. The company products pipeline includes TERN- 701, TERN-501 +/- FXR, TERN-601 and TERN-800 series. Its TERN-701 is used in chronic myeloid leukemia; TERN-601 is used in the treatment of obesity and TERN-501 is used in fixed-dose combinations for NASH treatment. It operates offices in the US. Terns Pharmaceuticals is headquartered in Foster City, California, the US.

For a complete picture of TERN-501’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.